Nasal sprayed particle deposition in a human nasal cavity under different inhalation conditions.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 27 11 2018
accepted: 06 08 2019
entrez: 7 9 2019
pubmed: 7 9 2019
medline: 10 3 2020
Statut: epublish

Résumé

Deposition of polydisperse particles representing nasal spray application in a human nasal cavity was performed under transient breathing profiles of sniffing, constant flow, and breath hold. The LES turbulence model was used to describe the fluid phase. Particles were introduced into the flow field with initial spray conditions, including spray cone angle, insertion angle, and initial velocity. Since nasal spray atomizer design determines the particle conditions, fifteen particle size distributions were used, each defined by a log-normal distribution with a different volume mean diameter (Dv50). Particle deposition in the anterior region was approximately 80% when Dv50 > 50μm, and this decreased to 45% as Dv50 decreased to 10μ m for constant and sniff breathing conditions. The decrease in anterior deposition was countered with increased deposition in the middle and posterior regions. The significance of increased deposition in the middle region for drug delivery shows there is potential for nasal delivered drugs to reach the highly vascularised mucosal walls in the main nasal passages. For multiple targeted deposition sites, an optimisation equation was introduced where deposition results of any two targeted sites could be combined and a weighting between 0 to 1 was applied to each targeted site, representing the relative importance of each deposition site.

Identifiants

pubmed: 31490971
doi: 10.1371/journal.pone.0221330
pii: PONE-D-18-34073
pmc: PMC6730903
doi:

Substances chimiques

Aerosols 0

Banques de données

figshare
['10.6084/m9.figshare.8040278']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0221330

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Aerosol Med. 2001 Summer;14(2):267-80
pubmed: 11681658
Pharm Res. 2002 Jan;19(1):1-6
pubmed: 11837692
Drug Discov Today. 2002 Dec 1;7(23):1184-9
pubmed: 12547019
Otolaryngol Head Neck Surg. 2004 Jan;130(1):5-24
pubmed: 14726906
Crit Rev Ther Drug Carrier Syst. 2004;21(1):21-66
pubmed: 15099184
J Aerosol Med. 2004 Fall;17(3):249-59
pubmed: 15625817
Pharm Res. 2005 Nov;22(11):1871-8
pubmed: 16091994
J Aerosol Med. 2007 Spring;20(1):59-74
pubmed: 17388754
J Aerosol Med. 2007 Winter;20(4):495-508
pubmed: 18158721
Comput Biol Med. 2008 Jun;38(6):713-26
pubmed: 18468593
Inhal Toxicol. 2009 Jun;21(7):607-18
pubmed: 19459775
J Biomech. 2009 Jul 22;42(10):1553-9
pubmed: 19501360
Laryngoscope. 2009 Oct;119(10):1975-82
pubmed: 19655385
J R Soc Interface. 2010 Mar 6;7(44):515-27
pubmed: 19740920
J Aerosol Sci. 2011 Jan 1;42(1):52-63
pubmed: 21339833
Int Forum Allergy Rhinol. 2011 Mar-Apr;1(2):128-35
pubmed: 22287331
J Pharm Sci. 2013 Mar;102(3):1024-35
pubmed: 23303644
Pharm Res. 2014 Aug;31(8):1930-7
pubmed: 24549819
J Aerosol Med Pulm Drug Deliv. 2015 Feb;28(1):59-67
pubmed: 24914675
Comput Biol Med. 2015 Jun;61:8-18
pubmed: 25862997
J Aerosol Med Pulm Drug Deliv. 2016 Apr;29(2):153-66
pubmed: 26270330
Prog Clin Biol Res. 1989;292:261-72
pubmed: 2657766
Comput Biol Med. 2016 Feb 1;69:166-80
pubmed: 26773939
Int Forum Allergy Rhinol. 2016 Nov;6(11):1204-1210
pubmed: 27315490
Comput Biol Med. 2016 Oct 1;77:40-8
pubmed: 27509293
Eur J Pharm Sci. 2018 Feb 15;113:77-94
pubmed: 28890203
J Biomech. 2017 Nov 7;64:59-68
pubmed: 28893392
Clin Biomech (Bristol, Avon). 2019 Jun;66:88-96
pubmed: 29079097
Int J Numer Method Biomed Eng. 2018 Apr;34(4):e2946
pubmed: 29172251
Int J Numer Method Biomed Eng. 2018 May;34(5):e2968
pubmed: 29453801
Mol Pharm. 2018 Apr 2;15(4):1392-1402
pubmed: 29485888
Pharm Res. 2018 Mar 26;35(5):108
pubmed: 29582159
Comput Biol Med. 2018 Sep 1;100:62-73
pubmed: 29975856

Auteurs

Hadrien Calmet (H)

Barcelona Supercomputing Center (BSC-CNS), Department of Computer Applications in Science and Engineering, Barcelona, Spain.

Kiao Inthavong (K)

School of Engineering (Mechanical & Automotive), RMIT University, Bundoora, Victoria, Australia.

Beatriz Eguzkitza (B)

Barcelona Supercomputing Center (BSC-CNS), Department of Computer Applications in Science and Engineering, Barcelona, Spain.

Oriol Lehmkuhl (O)

Barcelona Supercomputing Center (BSC-CNS), Department of Computer Applications in Science and Engineering, Barcelona, Spain.

Guillaume Houzeaux (G)

Barcelona Supercomputing Center (BSC-CNS), Department of Computer Applications in Science and Engineering, Barcelona, Spain.

Mariano Vázquez (M)

Barcelona Supercomputing Center (BSC-CNS), Department of Computer Applications in Science and Engineering, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH